Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - non-ionic detergents; phosphoric acid - liquid concentrate - non-ionic detergents emulsifiers & surfactants-noni active 30.0 g/l; phosphoric acid mineral-phosphorus-acid active 1152.0 g/l - dairy cleanser - milking equipment | milking machine - milkstone removal | milk fat | milk protein | mineral deposits

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dasco proprietary limited - alkaline salts; chlorine present as sodium dichloroisocyanurate; sodium hydroxide - wettable powder - alkaline salts cleanser/sanitiser active 226.0 g/kg; chlorine present as sodium dichloroisocyanurate mineral-chlorine active 25.0 g/kg; sodium hydroxide mineral-sodium-base active 740.0 g/kg - dairy cleanser - milk plant | dairy processing applications - general disinfection | antiviral agent | aviaries | catteries | detergent | feeding utensils | flesh wounds | floor | germicidal detergent | kennel | mastitis | mould growth | poultry cages | protozoans | stables | toilets (not septic) | walls

Canada - English - Health Canada

pro doc limitee - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics

Canada - English - Health Canada

pro doc limitee - propafenone hydrochloride - tablet - 300mg - propafenone hydrochloride 300mg - class ic antiarrythmics

United States - English - NLM (National Library of Medicine)

ethex - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - tablet, film coated - 150 mg - in patients without structural heart disease, propafenone hcl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms. as with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the functional av refractory period is recommended. the use of propafenone in patients with chronic atrial fibrillation has not been evaluated. propafenone should not be used to control ventricular rate during atrial fibrillation. propafenone is also indicated for the treatment of initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients w

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - disodium gadoxetate, quantity: 181.43 mg/ml - injection, solution - excipient ingredients: water for injections; trisodium caloxetate; trometamol; hydrochloric acid; sodium hydroxide - this medicinal product is for diagnostic use only. primovist is indicated for use in adults for the enhancement of magnetic resonance imaging (mri) of focal liver lesion

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - disodium gadoxetate, quantity: 181.43 mg/ml - injection, solution - excipient ingredients: trometamol; sodium hydroxide; hydrochloric acid; water for injections; trisodium caloxetate - this medicinal product is for diagnostic use only. primovist is indicated for use in adults for the enhancement of magnetic resonance imaging (mri) of focal liver lesion

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - disodium gadoxetate, quantity: 181.43 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; trisodium caloxetate; water for injections; sodium hydroxide; trometamol - this medicinal product is for diagnostic use only. primovist is indicated for use in adults for the enhancement of magnetic resonance imaging (mri) of focal liver lesion

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - disodium gadoxetate, quantity: 181.43 mg/ml - injection, solution - excipient ingredients: trisodium caloxetate; sodium hydroxide; trometamol; water for injections; hydrochloric acid - this medicinal product is for diagnostic use only. primovist is indicated for use in adults for the enhancement of magnetic resonance imaging (mri) of focal liver lesion

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - disodium gadoxetate, quantity: 181.43 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; trisodium caloxetate; trometamol; sodium hydroxide - this medicinal product is for diagnostic use only. primovist is indicated for use in adults for the enhancement of magnetic resonance imaging (mri) of focal liver lesion